Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07510724 | Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab(IKF-ReWoLuTe) | recruiting | — | 240 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Apr 3, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY |
| 2 |
| Apr 2, 2026 |
| clinicaltrials |
| NCT05746325 | Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer | recruiting | N/A | 5 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06114108 | Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients(salVage) | recruiting | N/A | 128 | Swiss Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06840704 | Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer(Relief) | recruiting | Phase 3 | 121 | Hunan Cancer HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07348965 | Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis | recruiting | N/A | 42 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07460999 | Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC)(Sing-a-Lung 2) | recruiting | N/A | 100 | Zealand University HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07487883 | Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors | recruiting | — | 80 | Peking University People's HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05665504 | Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer | recruiting | — | 250 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07354061 | Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)(TD-ENSEMBLE) | recruiting | Phase 1 / Phase 2 | 20 | Tang-Du HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07498933 | FAP-targeted PET/NIR in Lung Malignant Tumors | recruiting | — | 200 | Peking University People's HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505173 | Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer(HOPE-WBRT) | recruiting | Phase 2 | 74 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04762199 | MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer | recruiting | Phase 1 | 69 | Emory UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07015892 | Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial(ESCALADOR) | recruiting | Phase 3 | 300 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05254184 | KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC | recruiting | Phase 1 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06424067 | Phase 2 Study of Fingolimod in Lung Cancers | recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06769126 | Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study | recruiting | Phase 2 | 900 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06868732 | Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC | recruiting | Phase 1 | 288 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06687941 | A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors | recruiting | Phase 1 | 70 | Aptamer Sciences, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07055581 | Durvalumab as Consolidation for Patients LS-SCLC | recruiting | Phase 2 | 100 | Qian ChuOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07478809 | A Retrospective Real-World Study Based on RATIONALE-307 | recruiting | — | 109 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06123754 | Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC | recruiting | Phase 3 | 390 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492342 | Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC(K-NADIR) | recruiting | Phase 2 | 30 | Jianxing HeOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05805631 | Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | recruiting | Phase 2 | 23 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05669846 | Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC | recruiting | Phase 2 | 26 | Diwakar DavarOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07218601 | Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer | recruiting | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07336732 | Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations(KANNON-5) | recruiting | Phase 2 | 40 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07479095 | Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma(KETO-FDG Lung) | recruiting | N/A | 30 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07388771 | Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC） | recruiting | — | 500 | Qian ChuOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07477158 | Clinical Outcomes and Quality Of Life After Minimally Invasive Segmentectomy Versus Lobectomy for Lung Cancer | recruiting | — | 180 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07483112 | Fiber-Boost Randomized Controlled Trial(Fiber-Boost) | recruiting | N/A | 42 | Cantonal Hospital of St. GallenOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT07479277 | Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC(E-SEAL) | recruiting | N/A | 160 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480213 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)(DART-NK-SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05100069 | Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer | recruiting | — | 500 | TakedaINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06418204 | Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics(COSMIC) | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 2 | Mar 17, 2026 | clinicaltrials |
| NCT04499053 | Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05102110 | Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.(ORI-EGI-03) | recruiting | — | 450 | Origin SciencesINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07339254 | Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study | recruiting | — | 40 | University of Southern CaliforniaOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07469709 | A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks(PRO-ACTIVE) | recruiting | — | 850 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07467863 | Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC(DUO-NK-NSCLC) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05798845 | The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer | recruiting | Phase 2 | 124 | Shanghai Chest HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06439914 | First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy | recruiting | Phase 1 | 6 | Nerissa T. ViolaOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06681220 | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC(Relapsed SCLC) | recruiting | Phase 1 / Phase 2 | 166 | VA Office of Research and DevelopmentFED | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06775743 | ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 3, 2026source: clinicaltrials